Choosing a preclinical CRO is about more than comparing cost and turnaround time.
Preclinical studies often determine whether a therapeutic programme progresses, changes direction or stops. Biotech companies therefore need a partner that can generate robust data, understand the scientific question and maintain a clear clinical line of sight.
Scientifically relevant models
A CRO should be able to explain why a particular model is appropriate, what aspects of the disease it represents and where its limitations lie.
Established cell lines remain valuable, particularly during early screening, but they may not fully reflect the heterogeneity seen in patients. Patient-derived models can provide an additional layer of evidence by allowing therapeutics to be assessed across biologically diverse samples in 2D or 3D culture and under hypoxia as well as normoxic conditions.
The most complex model is not always the best model. Selection should be driven by the decision the study needs to support.
Disease-specific expertise
Technical capability should be supported by a strong understanding of the disease area.
In oncology, this includes knowledge of tumour biology, appropriate controls, clinically relevant comparators and meaningful study endpoints.
A valuable CRO partner should be prepared to contribute scientifically at the experimental planning stage, identify risks early and challenge assumptions where necessary, rather than simply carrying out a predefined list of experiments.
Flexibility and communication
Preclinical development rarely follows a completely predictable path.
Unexpected findings may reveal a responder population, suggest a new combination strategy or show that a model is unsuitable. A strong CRO should be able to adapt while maintaining clear and regular communication throughout the project.
Direct access to the scientists carrying out the work can also ensure that important observations are discussed and acted on quickly.
Robust, decision-relevant data
Biotech companies need data that are clear, traceable and supported by appropriate controls.
Negative or unexpected findings can be just as valuable as positive results when reported transparently and interpreted properly. The aim should be to provide evidence that supports confident development decisions.
A clear clinical line of sight
Preclinical studies should not be designed in isolation.
A translational CRO considers how each experiment supports the wider development pathway, whether that means selecting relevant models and endpoints, identifying potential biomarkers, understanding variation in response or generating evidence for future investment, regulatory or clinical-development discussions.
At Inaphaea BioLabs, we combine oncology expertise with established cell lines, patient-derived cancer models and functional assays to create tailored preclinical programmes. We have applied these principles to all of the evaluation programmes from our parent company ValiRx, allowing them to make informed decisions about asset in licensing.
Our patient-derived model biobank enables therapeutics to be evaluated across biologically diverse samples, helping researchers explore tumour heterogeneity and generate evidence that may better reflect the intended patient population.
Ultimately, the right CRO should not only ask which experiments need to be completed.
It should ask which decision the biotech company needs to make and design the study with a clear clinical line of sight towards that next step.